Heron Therapeutics, Inc. (HRTX) stock
HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.27−0.01 (-3.26%)
Close on Nov 18, 2026Market cap $51.83MP/E –Yield –
Heron Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Heron Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $151.18M, up 1.0% year over year. For fiscal 2025 it was $154.90M, up 7.4% from the year before. The highest annual figure on record is $154.90M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $154.90M | +7.4% |
| FY2024 | Dec 31, 2024 | $144.29M | +13.6% |
| FY2023 | Dec 31, 2023 | $127.04M | +18.0% |
| FY2022 | Dec 31, 2022 | $107.67M | +24.7% |
| FY2021 | Dec 31, 2021 | $86.35M | -2.6% |
| FY2020 | Dec 31, 2020 | $88.64M | -39.3% |
| FY2019 | Dec 31, 2019 | $145.97M | +88.4% |
| FY2018 | Dec 31, 2018 | $77.47M | +151.8% |
| FY2017 | Dec 31, 2017 | $30.77M | +2305.6% |
| FY2016 | Dec 31, 2016 | $1.28M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $37.67M | +1.3% |
| Q1 FY2026 | Mar 31, 2026 | $34.71M | -10.8% |
| Q4 FY2025 | Dec 31, 2025 | $40.59M | -0.5% |
| Q3 FY2025 | Sep 30, 2025 | $38.21M | +16.5% |
| Q2 FY2025 | Jun 30, 2025 | $37.20M | +3.3% |
| Q1 FY2025 | Mar 31, 2025 | $38.90M | +12.2% |
| Q4 FY2024 | Dec 31, 2024 | $40.78M | +19.1% |
| Q3 FY2024 | Sep 30, 2024 | $32.81M | +4.4% |
| Q2 FY2024 | Jun 30, 2024 | $36.02M | +13.4% |
| Q1 FY2024 | Mar 31, 2024 | $34.67M | +17.1% |
| Q4 FY2023 | Dec 31, 2023 | $34.23M | +14.0% |
| Q3 FY2023 | Sep 30, 2023 | $31.43M | +18.4% |
| Q2 FY2023 | Jun 30, 2023 | $31.76M | +15.0% |
| Q1 FY2023 | Mar 31, 2023 | $29.62M | +26.3% |
| Q4 FY2022 | Dec 31, 2022 | $30.03M | +45.4% |
| Q3 FY2022 | Sep 30, 2022 | $26.56M | +14.3% |
| Q2 FY2022 | Jun 30, 2022 | $27.63M | +23.1% |
| Q1 FY2022 | Mar 31, 2022 | $23.46M | +17.2% |
| Q4 FY2021 | Dec 31, 2021 | $20.66M | +0.2% |
| Q3 FY2021 | Sep 30, 2021 | $23.23M | +16.4% |
| Q2 FY2021 | Jun 30, 2021 | $22.44M | -1.0% |
| Q1 FY2021 | Mar 31, 2021 | $20.02M | -21.2% |
| Q4 FY2020 | Dec 31, 2020 | $20.61M | -41.3% |
| Q3 FY2020 | Sep 30, 2020 | $19.97M | -53.2% |
| Q2 FY2020 | Jun 30, 2020 | $22.67M | -38.2% |
| Q1 FY2020 | Mar 31, 2020 | $25.40M | -19.6% |
| Q4 FY2019 | Dec 31, 2019 | $35.08M | +21.6% |
| Q3 FY2019 | Sep 30, 2019 | $42.62M | +115.4% |
| Q2 FY2019 | Jun 30, 2019 | $36.66M | +112.2% |
| Q1 FY2019 | Mar 31, 2019 | $31.60M | +173.2% |
| Q4 FY2018 | Dec 31, 2018 | $28.84M | +186.9% |
| Q3 FY2018 | Sep 30, 2018 | $19.79M | +130.8% |
| Q2 FY2018 | Jun 30, 2018 | $17.28M | +103.0% |
| Q1 FY2018 | Mar 31, 2018 | $11.57M | +218.5% |
| Q4 FY2017 | Dec 31, 2017 | $10.05M | +686.0% |
| Q3 FY2017 | Sep 30, 2017 | $8.57M | – |
| Q2 FY2017 | Jun 30, 2017 | $8.51M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.63M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.28M | – |
See a number that looks wrong?